NCT03049267View on ClinicalTrials.gov

Short-term Safety, Efficacy and Mode of Action of Apremilast in Moderate Suppurative Hidradenitis

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 2, 2017

Primary Completion Date

December 6, 2017

Study Completion Date

June 28, 2018

Conditions
Hidradenitis Suppurativa
Interventions
DRUG

Apremilast

Fifteen patients will be supplied of apremilast for daily oral use; 16 weeks.

DRUG

Placebo Oral Tablet

Five patients will be supplied with placebo tablets with identical labeling as apremilast for daily use; 16 weeks.

Trial Locations (1)

Unknown

Erasmus University Medical Center, Rotterdam

Sponsors

Collaborators (1)

Celgene
All Listed Sponsors
collaborator

Celgene

INDUSTRY

lead

M.B.A. van Doorn

OTHER